TY - JOUR
T1 - Thiazolyl-isatin derivatives
T2 - Synthesis, in silico studies, in vitro biological profile against breast cancer cells, mRNA expression, P-gp modulation, and interactions of Akt2 and VIM proteins
AU - Freitas, Luiz Alberto Barros
AU - Souza, Carolina
AU - Lima, Beatriz Silva
AU - Duarte, Denise
AU - Gomes, Paulo André Teixeira de Moraes
AU - Ramos, Camila Gabriela Costa
AU - Costa, Valécia de Cássia Mendonça
AU - Pitta, Maira Galdino da Rocha
AU - Rêgo, Moacyr Jesus Barreto de Melo
AU - de Simone, Carlos Alberto
AU - Videira, Mafalda
AU - Leite, Ana Cristina Lima
N1 - Funding Information:
This work was funded by Conselho Nacional de Desenvolvimento Científico e Tecnológico ( CNPq ) and Fundação de Amparo à Ciência e Tecnologia de Pernambuco ( FACEPE ). Ana Cristina Lima Leite acknowledges support from a CNPq senior fellowship. The authors gratefully acknowledge the Departamento de Química Fundamental (DQF- UFPE ) for recording the 1 H NMR, and 13 C NMR spectra of compounds. We also thank the Centro de Tecnologias Estratégicas do Nordeste (CETENE) for recording the MS spectra of compounds. Special thanks to DAIRIX Analytical Equipment, for kindly allowing the use of the Rigaku Mini XtaLAB diffractometer installed at the Institute of Physics of São Carlos- USP for demonstration purposes.
Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/5/1
Y1 - 2024/5/1
N2 - The literature reports that thiazole and isatin nuclei present a range of biological activities, with an emphasis on anticancer activity. Therefore, our proposal was to make a series of compounds using the molecular hybridization strategy, which has been used by our research group, producing hybrid molecules containing the thiazole and isatin nuclei. After structural planning and synthesis, the compounds were characterized and evaluated in vitro against breast cancer cell lines (T-47D, MCF-7 and MDA-MB-231) and against normal cells (PBMC). The activity profile on membrane proteins involved in chemoresistance and tumorigenic signaling proteins was also evaluated. Among the compounds tested, the compounds 4c and 4a stood out with IC50 values of 1.23 and 1.39 μM, respectively, against the MDA-MB-231 cell line. Both compounds exhibited IC50 values of 0.45 μM for the MCF-7 cell line. Compounds 4a and 4c significantly decreased P-gp mRNA expression levels in MCF-7, 4 and 2 folds respectively. Regarding the impact on tumorigenic signaling proteins, compound 4a inhibited Akt2 in MDA-MB-231 and compound 4c inhibited the mRNA expression of VIM in MCF-7.
AB - The literature reports that thiazole and isatin nuclei present a range of biological activities, with an emphasis on anticancer activity. Therefore, our proposal was to make a series of compounds using the molecular hybridization strategy, which has been used by our research group, producing hybrid molecules containing the thiazole and isatin nuclei. After structural planning and synthesis, the compounds were characterized and evaluated in vitro against breast cancer cell lines (T-47D, MCF-7 and MDA-MB-231) and against normal cells (PBMC). The activity profile on membrane proteins involved in chemoresistance and tumorigenic signaling proteins was also evaluated. Among the compounds tested, the compounds 4c and 4a stood out with IC50 values of 1.23 and 1.39 μM, respectively, against the MDA-MB-231 cell line. Both compounds exhibited IC50 values of 0.45 μM for the MCF-7 cell line. Compounds 4a and 4c significantly decreased P-gp mRNA expression levels in MCF-7, 4 and 2 folds respectively. Regarding the impact on tumorigenic signaling proteins, compound 4a inhibited Akt2 in MDA-MB-231 and compound 4c inhibited the mRNA expression of VIM in MCF-7.
KW - Akt2 and VIM
KW - Breast cancer
KW - Isatin
KW - Thiazole
KW - Thiosemicarbazone
UR - http://www.scopus.com/inward/record.url?scp=85188922579&partnerID=8YFLogxK
U2 - 10.1016/j.cbi.2024.110954
DO - 10.1016/j.cbi.2024.110954
M3 - Article
C2 - 38518852
AN - SCOPUS:85188922579
SN - 0009-2797
VL - 394
JO - Chemico-Biological Interactions
JF - Chemico-Biological Interactions
M1 - 110954
ER -